<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00232830</url>
  </required_header>
  <id_info>
    <org_study_id>EC03-03</org_study_id>
    <nct_id>NCT00232830</nct_id>
  </id_info>
  <brief_title>The Study to Assess AMI Treated With Balloon Angioplasty.</brief_title>
  <acronym>TYPHOON</acronym>
  <official_title>Trial to Assess the Use of the Cypher TM Stent in Acute Myocardial Infarction Treated With Balloon Angioplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cordis Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cordis Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to assess the effectiveness and safety of the CYPHER™
      (CYPHER SELECT™) (Sirolimus-eluting) stent in reducing the occurrence of a composite endpoint
      of target vessel failure (TVF) in subjects treated for acute myocardial infarction as
      compared to a bare metal stent.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an international, multicenter (up to 52 sites), randomized, single-blind study in
      patients with an acute myocardial infarction treated with the CYPHER™ (Sirolimus-eluting)
      stent as compared to the bare stents.

      Patients with de novo native coronary artery lesions will be treated with the CYPHER™
      (Sirolimus-eluting) stent or a bare stent. Subjects will be followed at 30 days, 6 months and
      at 1, 3, 4 and 5 years post-procedure. 200 subjects will have an angiographic follow-up at 8
      months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of target vessel failure (TVF) defined as target vessel revascularization, recurrent myocardial infarction, or cardiac death that could not be clearly attributed to a vessel other than the target vesselpost-procedure.</measure>
    <time_frame>1 and 6 months and at 1, 3, 4, and 5 years post-procedure.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>cardiac death</measure>
    <time_frame>1, 3, 4 and 5 years post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>recurrence of myocardial infarction</measure>
    <time_frame>1, 3, 4 and 5 years post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>revascularization of the target vessel (TVR)</measure>
    <time_frame>1, 3, 4 and 5 years post-procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>recurrence of ischemia</measure>
    <time_frame>1, 3, 4 and 5 years post-procedure</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">715</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cypher Sirolimus-eluting Coronary Stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bare-metal stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>drug-eluting stent</intervention_name>
    <description>Cypher Sirolimus-eluting Coronary Stent</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>bare-metal stent</intervention_name>
    <description>any bare-metal stent brand</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have prolonged, continuous (lasting at least 20 minutes) chest pain despite
             administration of nitrates and onset within 12 hours of randomization, and one of the
             following:

               1. ST segment elevation &gt;=1mm in standard leads and &gt;=2mm in 2 or more contiguous
                  precordial leads with reciprocal ST depression

               2. New or presumably new left bundle branch block (LBBB)

          2. The culprit lesion must be identified on a de novo native coronary artery and an
             emergency angioplasty must be possible. The culprit site must be visualized before the
             stent implantation;

        Exclusion Criteria:

          1. Killip class &gt; 2 upon arrival to the cath-lab;

          2. Significant (&gt;50%) stenosis proximal or distal to the target lesion that might require
             revascularization or impede inflow or runoff;

          3. Evidence of massive thrombus in the infarct related artery distally to the culprit
             lesion;

          4. Documented left ventricular ejection fraction &lt;=30%;

          5. Target lesion is located in an arterial or venous by-pass graft;

          6. ECG documented evidence of prior myocardial infarction;

          7. Patient who received thrombolytic therapy for the current AMI before enrollment in
             this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Spaulding, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HOPITAL COCHIN, René Descartes University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christoph Bode, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Freiburg, Albert-Ludwigs-Universitätskliniken</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>HOPITAL COCHIN, René Descartes University</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Freiburg, Albert-Ludwigs-Universitätskliniken</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Spaulding C, Henry P, Teiger E, Beatt K, Bramucci E, Carrié D, Slama MS, Merkely B, Erglis A, Margheri M, Varenne O, Cebrian A, Stoll HP, Snead DB, Bode C; TYPHOON Investigators. Sirolimus-eluting versus uncoated stents in acute myocardial infarction. N Engl J Med. 2006 Sep 14;355(11):1093-104.</citation>
    <PMID>16971716</PMID>
  </results_reference>
  <results_reference>
    <citation>Rozenman Y, Witzling V, Tamari I, Turkisher V, Kriviski M, Bode C, Henry P, Teiger E, Cebrian A, Stoll HP, Spaulding C. Impact of stent length on restenosis in patients with acute myocardial infarction treated with primary percutaneous coronary intervention: analysis based on data from the Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON). EuroIntervention. 2009 Jun;5(2):219-23.</citation>
    <PMID>19527979</PMID>
  </results_reference>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2005</study_first_submitted>
  <study_first_submitted_qc>October 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 5, 2005</study_first_posted>
  <last_update_submitted>September 15, 2009</last_update_submitted>
  <last_update_submitted_qc>September 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Hans-Peter Stoll</name_title>
    <organization>Cordis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

